Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin and Metformin as Initial Therapy in Type 2 Diabetes
NCT00859898Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2009
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin + Metformin XR, Dapagliflozin + Placebo and Metformin XR + Placebo (3 arms). Primary endpoint: Change From Baseline in Hemoglobin A1c at 24 weeks. Started Apr 2009; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00859898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00859898.